Ignite Creation Date:
2025-12-24 @ 12:17 PM
Ignite Modification Date:
2026-01-06 @ 11:43 AM
Study NCT ID:
NCT03872661
Status:
RECRUITING
Last Update Posted:
2024-12-06
First Post:
2019-02-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
Sponsor:
Sun Yat-sen University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-03-01
Start Date Type:
ACTUAL
Primary Completion Date:
2025-12-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-12-01
Completion Date Type:
ESTIMATED
First Submit Date:
2019-02-27
First Submit QC Date:
None
Study First Post Date:
2019-03-13
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-12-05
Last Update Post Date:
2024-12-06
Last Update Post Date Type:
ACTUAL